Verici Dx Plc (VRCI) AI Stock Analysis

• Market Cap: £10.97M
• Dividend Yield: N/A
• Average Volume (3M): 6.85M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.75
• Revenue Growth: -57.03%
• EPS Growth: -15.71%
• Country: UK
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,513,394,200
• 10 Day Avg. Volume: 9,044,876
• 30 Day Avg. Volume: 6,845,005
• PEG Ratio: 0.04
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.38
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: 0.75p ▲(4.72% Upside)

Verici Dx Plc's overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company's strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.

Positive Factors

Niche transplant diagnostics focus

Verici's specialization in blood-based molecular diagnostics and AI for kidney transplant care creates a durable niche. Focused, clinically targeted assays (pre- and post-transplant) support deeper clinical integration, higher switching costs, and the potential for steady volume growth as adoption expands.

Regulatory and quality accreditations

CAP and ISO 27001 certifications and related operational milestones enhance laboratory credibility and data-security posture. These accreditations reduce adoption friction with hospitals, labs and payers, supporting longer-term commercial traction and partnership opportunities across transplant centers.

Conservative capital structure, low leverage

A strong equity position and low debt provide financial flexibility while the business scales and works toward profitability. Low leverage reduces refinancing and interest risks, preserving capacity to invest in lab capacity, R&D, and commercialization during periods of negative cash flow.

Negative Factors

Sustained net losses and negative margins

Persistent negative EBIT and net income signal unresolved profitability challenges. Continued losses erode retained capital, constrain reinvestment, and require either material margin improvement or ongoing external funding to sustain operations and scale commercial activities over the medium term.

Negative operating and free cash flow; financing reliance

Negative operating and free cash flows with material cash from financing indicate dependency on external capital. This reliance raises dilution and execution risk, and makes expansion sensitive to capital markets access rather than self-funded growth from test-volume cash generation.

Commercial adoption and reimbursement dependency

Long-term revenue hinges on clinician adoption and stable payer reimbursement. Slow uptake at transplant centers or adverse coverage decisions would structurally limit test volumes and cash generation, making scaling and margin improvement contingent on favorable provider and payer dynamics.

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

How the Company Makes Money

Verici Dx generates revenue primarily through the sale of its diagnostic tests to hospitals, transplant centers, and healthcare providers. The company benefits from a fee-for-service model, where it charges healthcare institutions for each test performed. Additionally, Verici Dx may explore partnerships and collaborations with pharmaceutical companies and research institutions, which can provide further revenue opportunities through joint ventures, research grants, or co-development agreements. The expansion of its test offerings and the establishment of new relationships within the healthcare ecosystem are significant factors contributing to its earnings.

Verici Dx Plc Financial Statement Overview

Summary

Verici Dx Plc is experiencing revenue growth but continues to face profitability challenges, with ongoing net losses impacting return metrics. The balance sheet remains stable with low leverage, although cash flow issues persist due to negative operating cash flows, indicating the need for careful financial management and potentially further external financing.

Income Statement

Verici Dx Plc has shown a significant increase in total revenue from 2023 to 2024, indicating positive revenue growth. However, the company has consistently reported negative EBIT and net income figures, reflecting ongoing losses. The gross profit margin stands at 100% due to the absence of cost of goods sold, but negative net profit and EBIT margins highlight profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio, suggesting a conservative capital structure. However, the return on equity is negative due to net losses, which is a concern. The equity ratio indicates that a significant portion of the company's assets is financed by equity, which is a positive sign of financial stability.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, indicating cash outflows from core operations. Financing activities have provided substantial cash inflows, suggesting reliance on external financing. The operating cash flow to net income ratio is negative, reinforcing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.48M	3.34M	1.01M	0.00	0.00	0.00
Gross Profit	1.56M	3.34M	1.01M	0.00	0.00	0.00
EBITDA	-7.11M	-5.15M	-7.88M	-10.50M	-7.15M	-2.10M
Net Income	-6.91M	-5.87M	-8.73M	-11.36M	-8.33M	-7.10M
Balance Sheet
Total Assets	4.54M	7.49M	7.44M	14.30M	13.79M	20.31M
Cash, Cash Equivalents and Short-Term Investments	467.00K	4.06M	2.65M	9.80M	10.34M	17.75M
Total Debt	282.00K	371.00K	540.00K	700.00K	0.00	73.55K
Total Liabilities	2.06M	2.23M	3.88M	2.80M	1.80M	681.89K
Stockholders Equity	2.48M	5.26M	3.56M	11.51M	11.98M	19.62M
Cash Flow
Free Cash Flow	-6.37M	-6.21M	-7.39M	-11.38M	-7.30M	-1.32M
Operating Cash Flow	-5.55M	-6.02M	-7.16M	-10.07M	-6.34M	-1.28M
Investing Cash Flow	108.19K	61.00K	-231.00K	-1.31M	-965.86K	-237.16K
Financing Cash Flow	-282.64K	7.32M	-27.00K	12.67M	-73.55K	26.75M

Verici Dx Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.75, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 37.77 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VRCI.

Verici Dx Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	67 Neutral	£106.30M	18.22	8.71%	―	-1.43%	28.57%
VRCI	58 Neutral	£10.97M	-0.30	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	47 Neutral	£11.07M	-1.16	-153.92%	―	90.42%	79.21%
ABDX	45 Neutral	£15.06M	-6.32	-90.48%	―	37.39%	-126.19%
RENX	43 Neutral	£25.13M	-0.40	425.97%	―	-4.48%	61.09%
OBD	38 Underperform	£11.80M	-0.29	-407.49%	―	72.17%	79.03%

Verici Dx Plc Corporate Events

Verici Dx Achieves Successful CAP Accreditation Audit

Verici Dx Plc has successfully completed its second biennial CAP accreditation audit for its clinical laboratory, demonstrating its commitment to maintaining high standards in clinical laboratory practices. This accreditation ensures that Verici Dx can consistently provide reliable test results, reinforcing its position as a trusted partner to clinicians and enhancing personalized care for kidney transplant patients.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Expands Reach with Prime Health Services Agreement

Verici Dx Plc has entered into a Provider Participation Agreement with Prime Health Services, a leading US-based healthcare technology company with a vast Preferred Provider Organization network. This agreement is a significant step for Verici Dx, as it expands its commercial reach and patient network, enhancing its coverage from private payors and potentially increasing its market presence in the healthcare diagnostics sector.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.

Verici Dx Achieves ISO 27001 Audit Success, Enhancing Industry Trust

Verici Dx Plc has successfully completed its annual ISO 27001:2022 surveillance audit, reaffirming its commitment to data privacy and security. This achievement strengthens its reputation as a trusted partner in the organ transplant diagnostics industry, ensuring compliance with global standards and maintaining stakeholder confidence.

The most recent analyst rating on (GB:VRCI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.